Karen Crew Discusses the Importance and Positive Impacts of the Multiple Myeloma Research Foundation

Karen Crew

March 29, 2021

Melanoma cancer survivor Karen Crew recently discussed the importance and positive impacts of the Multiple Myeloma Research Foundation.

BOCA RATON, FL / Curing multiple myeloma is the mission of the Multiple Myeloma Research Foundation (MMRF). Multiple myeloma is cancer formed in the type of white blood cell known as the plasma cell. Properly functioning plasma cells help fight infections. However, cancerous plasma cells can pile up in the bone marrow and push healthy blood cells out. These cancer cells create abnormal proteins that cause health issues rather than create beneficial antibodies. Melanoma cancer survivor Karen recently discussed the importance of the Multiple Myeloma Research Foundation.

Karen Crew is a supporting member of the Multiple Myeloma Research Foundation. She explained that the foundation works in the field of cancer research. Their approach to finding a cure is creating disciplined disruptions to the status quo. Karen Crew explained that those at MMRF come from a variety of pharmaceutical and business backgrounds. They’ve developed ways to streamline communication, improve efficiency, and accelerate the results of studies. The goal is to accelerate the discoveries that currently have the ability to improve patient lives.

“Patients are the top priority at MMRF,” Crew said. “The foundation is constantly working toward a cure, and until then, they will improve survival rates and improve the lives of those living with multiple myeloma right now.”

Karen emphasized that the foundation prioritizes patients through leveraging industry relationships to accelerate clinical trials, create breakthrough treatments, and improve overall mental and physical well-being.

“The Multiple Myeloma Research Foundation has been making major advancements in the development of a cure for multiple myeloma for 20 years,” Karen Crew said.

The MMRF was founded in 1998 and brought 350 researchers into the field of myeloma research. In the early 2000s, the foundation had created a multi-center tissue bank with more than 4,000 samples, opened more than 80 clinical trials, and completed groundbreaking genome sequencing. Karen Crew stated that the advancements continued into the 2010s, as the foundation launched the MMRF MyDRUG study as the first platform trial in myeloma.

Karen Crew added that this year, the foundation worked harder than ever as the pandemic took hold. They’ve now launched the MMRF CureCloud, which is the first at-home genomic testing platform. This will allow data from immune and genomic landscapes to combine and become more powerful than ever before.

“This foundation has decades of experience and has proven its course of constant innovation,” Karen Crew said. “We are clearly on the path to finding a cure for multiple myeloma.”

Karen Crew finished by encouraging others to learn more or make a charitable contribution at TheMMRF.org.